Company intelligence / Profile preview
DJS Antibodies
Oxford, England, United Kingdomdjsantibodies.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead program DJS-002 is a potential first-in-class LPAR1 antagonist antibody in investigational preclinical studies for IPF and other fibrotic diseases
- Therapeutic areas
- PulmonologyImmunologyRheumatology
- Modalities
- Antibody therapeuticsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DJS Antibodies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DJS Antibodies.